Special considerations regarding CMV in lung transplantation.
Lung transplant recipients, more than other organ transplant recipients, are at particular risk for cytomegalovirus (CMV) infection and disease. A major factor in improving management of the lung transplant patient is the ability to prevent or minimize CMV disease, which itself is a major risk factor for opportunistic fungal infections and obliterative bronchiolitis. Strategies being evaluated to improve CMV prophylaxis and consequently graft and patient survival include longer-than-standard courses of prophylactic IV ganciclovir, sequential IV/oral therapy, addition of CMV IG, examining the impact of newer immunosuppressive agents, the role of hypogammaglobulinemia, and potential investigational studies with newer antiviral agents.
Avery
R K
RK
Department of Infectious Diseases and Transplant Center, Cleveland Clinic Foundation, Ohio 44195, USA. averyr@ccf.org
D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000503:physiopathology* / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016040:Lung Transplantation / Q000276:immunology; D009894:Opportunistic Infections / Q000503:physiopathology* / Q000517:prevention & control; D011183:Postoperative Complications
D000998:Antiviral Agents; D007166:Immunosuppressive Agents